Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Other financing activities (2016 - 2025)

Neuroone Medical Technologies filings provide 6 years of Other financing activities readings, the most recent being $22920.0 for Q4 2025.

  • On a quarterly basis, Other financing activities rose 7.58% to $22920.0 in Q4 2025 year-over-year; TTM through Mar 2026 was -$172374.0, a N/A change, with the full-year FY2024 number at $20000.0, down 91.48% from a year prior.
  • Other financing activities hit $22920.0 in Q4 2025 for Neuroone Medical Technologies, up from $21305.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $183359.0 in Q1 2023 to a low of -$216599.0 in Q3 2024.
  • Median Other financing activities over the past 4 years was $37698.0 (2023), compared with a mean of $34962.6.
  • Biggest five-year swings in Other financing activities: skyrocketed 139.92% in 2023 and later tumbled 43.49% in 2024.
  • Neuroone Medical Technologies' Other financing activities stood at $15713.0 in 2022, then skyrocketed by 139.92% to $37698.0 in 2023, then tumbled by 43.49% to $21305.0 in 2024, then rose by 7.58% to $22920.0 in 2025.
  • The last three reported values for Other financing activities were $22920.0 (Q4 2025), $21305.0 (Q4 2024), and -$216599.0 (Q3 2024) per Business Quant data.